Discover Protalix BioTherapeutics' Q4 2024 earnings insights, including record revenues, pipeline advancements, and future growth prospects.

Protalix BioTherapeutics, Inc. , a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® ...

School of Medicine and Biosciences, University of West London, London W5 5RF, U.K. School of Medicine and Biosciences, University of West London, London W5 5RF, U.K. School of Pharmacy, University ...

The Company’s poster presentation will provide updates on their lead asset PP-007, a PEGylated carboxyhemoglobin bovine product, in AIS. Prolong recently completed enrollment for Part 3 of the ...

Institute of Advanced Technology, Westlake Institute for Advanced Study, Hangzhou 310024, Zhejiang, China School of Engineering, Westlake University, Hangzhou 310030, Zhejiang, China Institute of ...

To increase the limited space for the dosage increases in PEGylated aptamer therapy, therapeutic aptamers with a higher proportion of active aptamer moiety need to be developed. As we mentioned above, ...